Purpose of the Report: Ovarian cancer is usually diagnosed in an advanced stage of disease due to the absence of specific symptoms and a lack of sensitive diagnostic methods. Prostate-specific membrane antigen (PSMA) is expressed on prostate cancer cells but can be found in other tumors such as ovarian cancer.The aim of this pilot study was to evaluate the feasibility of using 68 Ga-PSMA-11 PET/CT in detection of ovarian neoplasm before surgical treatment. Patients and Methods: Eight women with mean age of 56.0 ± 16.2 years were included in the study. All patients underwent transvaginal ultrasound followed by CT scan of the chest and abdomen as qualification for surgery. Within a 1-week interval, PET/CT was performed on a Siemens Biograph scanner, 60 minutes after injection of 2 MBq/kg 68 Ga-PSMA-11. Results: In 3 cases (37.5%), the 68 Ga-PSMA-11 PET/CT was positive, whereas histological examination confirmed 2 serous ovarian cancer cases and 1 ovarian borderline tumor. The SUV max in the serous ovarian cancer was 8.7 and 4.1, and in the borderline ovarian tumor, it was 13.8. No correlation was found between antigen CA-125 level and 68 Ga-PSMA expression. Range of tumor SUV max was not correlated with stage of disease. The remaining 62.5% (5/8) were negative in 68 Ga-PSMA-11 PET/CT, and histopathology confirmed benign pelvic tumor. Conclusions:The initial experience supports the potential to use 68 Ga-PSMA-11 in ovarian cancer to differentiate malignant and benign tumors before surgery.This study was approved by the Ethical Committee of the Medical University of Warsaw (KB/2/A/2018).
Purpose Ovarian cancer is usually diagnosed in an advanced stage of disease due to the absence of specific symptoms and a lack of sensitive diagnostic methods. Prostate-specific membrane antigen (PSMA) is expressed on prostate cancer cells, but can be found in other tumours such as ovarian cancer. The aim of this pilot study was to evaluate the feasibility of using [68Ga]Ga-PSMA-11 PET/CT in detection of ovarian neoplasm before surgical treatment.Material and methods: Eight women with mean age of 56.0±16.2 years were included in the study. All patients underwent transvaginal ultrasound followed by CT scan of the chest and abdomen as qualification for surgery. Within a 1-week interval, PET/CT was performed on a Siemens Biograph scanner, 60 min after injection of 2 MBq/kg [68Ga]Ga-PSMA-11.Results: In three cases (37.5%) the [68Ga]Ga-PSMA-11 PET/CT was positive, whereas histological examination confirmed two serous ovarian cancer cases and one ovarian borderline tumour. The SUVmax in the serous ovarian cancer was 8.7 and 4.1, and in the borderline ovarian tumour it was 13.8. No correlation was found between antigen CA 125 level and [68Ga]Ga-PSMA expression. Range of tumour SUVmax was not correlated with stage of disease. The remaining 62.5% (5/8) were negative in [68Ga]Ga-PSMA-11 PET/CT and histopathology confirmed benign pelvic tumour.Conclusion The initial experience supports the potential to use [68Ga]Ga-PSMA-11 in ovarian cancer to differentiate malignant and benign tumours before surgery. This study was approved by the Ethical Committee of the Medical University of Warsaw (KB/2/A/2018).
Purpose Ovarian cancer is usually diagnosed in an advanced stage of disease due to the absence of specific symptoms and a lack of sensitive diagnostic methods. Prostate‑specific membrane antigen (PSMA) is expressed on prostate cancer cells, but can be found in other tumours such as ovarian cancer. The aim of this pilot study was to evaluate the feasibility of using [ 68 Ga]Ga-PSMA-11 PET/CT in detection of ovarian neoplasm before surgical treatment. Material and methods: Eight women with mean age of 56.0±16.2 years were included in the study. All patients underwent transvaginal ultrasound followed by CT scan of the chest and abdomen as qualification for surgery. Within a 1-week interval, PET/CT was performed on a Siemens Biograph scanner, 60 min after injection of 2 MBq/kg [ 68 Ga]Ga-PSMA-11. Results: In three cases (37.5%) the [ 68 Ga]Ga-PSMA-11 PET/CT was positive, whereas histological examination confirmed two serous ovarian cancer cases and one ovarian borderline tumour. The SUVmax in the serous ovarian cancer was 8.7 and 4.1, and in the borderline ovarian tumour it was 13.8. No correlation was found between antigen CA 125 level and [ 68 Ga]Ga-PSMA expression. Range of tumour SUVmax was not correlated with stage of disease. The remaining 62.5% (5/8) were negative in [ 68 Ga]Ga-PSMA-11 PET/CT and histopathology confirmed benign pelvic tumour. Conclusion The initial experience supports the potential to use [ 68 Ga]Ga-PSMA-11 in ovarian cancer to differentiate malignant and benign tumours before surgery. This study was approved by the Ethical Committee of the Medical University of Warsaw (KB/2/A/2018).
Fertility preservation is a procedure of conservative surgery which may be performed in the early stage of cervical cancer as radical trachelectomy. The aim of the study is to describe the first robotic radical trachelectomy in Poland with safe cervical sample extraction using an underpressure manipulator. Robotic abdominal trachelectomy was performed in a 42-year-old nullipara with squamous cell cervical carcinoma G2 using an underpressure manipulator. No complications were observed. Mobilization of the patient began the day after the surgical procedure. The long-term obstetric and oncologic outcome of this technique would be expected to match the outcome of the other radical trachelectomy techniques in the published literature. Using of an underpressure manipulator decreases the risk of cervical tumour spread during the surgery. To our knowledge, this is the first description of safe radical trachelectomy specimen extraction using an underpressure colpotomizer. StreszczenieLeczenie oszczędzające płodność może być rozważane w przypadku wczesnych stopni zaawansowania raka szyjki macicy jako radykalna trachelektomia. Celem pracy był opis pierwszej przeprowadzonej w Polsce radykalnej trachelektomii w asyście robota z użyciem podciśnieniowego manipulatora. Radykalną robotyczną trachelektomię z użyciem podciśnieniowego manipulatora przeprowadzono u 42-letniej nieródki z rozpoznaniem płaskonabłonkowego raka szyjki macicy G2. Okres około-i pooperacyjny przebiegał bez powikłań. Pacjentka została uruchomiona następnego dnia po operacji. W piśmiennictwie opisywane są długoterminowe korzystne wyniki położnicze i onkologicznej u pacjentek po przebytej radykalnej trachelektomii. Użycie podciśnieniowego manipulatora zmniejsza ryzyko rozprzestrzeniania się komórek guza w trakcie operacji. To pierwszy taki opis radykalnej robotycznej trachelektomii z użyciem podciśnieniowego manipulatora.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.